The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming the standard of care therapy Esbriet. PureTech Health’s treatment candidate also caused fewer gastrointestinal side effects in patients. That’s according to top-line data from the ongoing Phase…
News
Trevi Therapeutics announced that its ongoing Phase 2b clinical trial testing Haduvio (nalbuphine extended-release tablets) in people with idiopathic pulmonary fibrosis (IPF) who have chronic cough has reached 75% of its targeted patient enrollment. The Phase 2b CORAL trial (NCT05964335) is still seeking to recruit a…
The first patient has been dosed in a Phase 2b clinical trial of Endeavor Biomedicines’ investigational oral therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF). WHISTLE-PF (NCT06422884) seeks to enroll around 200 adults in 14 countries. The first patient was dosed in Australia. The study’s launch…
The Pulmonary Fibrosis Foundation (PFF) has launched “PF Basics: Info for Newly Diagnosed Patients,” a new educational program to help patients with pulmonary fibrosis (PF) and interstitial lung disease get answers to the most pressing questions about their disease after a recent diagnosis. “We heard from patients and caregivers…
MNKD-201, Mannkind’s inhaled formulation of nintedanib for treating idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in a Phase 1 clinical trial involving healthy volunteers — meeting the study’s primary goal. The trial’s results also showed that participants did not experience the typical adverse…
CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in the development of our lead asset, CAL101,…
The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and identify new targets for treatments that may halt or slow its progression. “This exciting collaboration with GSK will help ……
Researchers have identified a type of pro-fibrotic immune cell associated with pulmonary fibrosis (PF) in people who develop persistent breathing problems after recovering from COVID-19. The cells’ abundance correlated with the severity of fibrosis, or tissue scarring, as detected by CT scans. “The underlying cells and molecules that contribute…
Insilico Medicine’s ISM001-055 was generally safe and improved lung function in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a trial. The trial (NCT05938920) enrolled 71 patients with IPF across 21 sites in China who were randomly assigned to receive one of…
A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
